|
KMID : 0378019880310070119
|
|
New Medical Journal
1988 Volume.31 No. 7 p.119 ~ p.125
|
|
|
A Clinical Comparative Study of UNASYN^(®) (Sulbactam/Ampicillin) vs. Cefapiri Gentamycin in Surgical Infections Disease.
|
|
|
|
|
Abstract
|
|
|
A clinical study of evaluate the efficacy and safety of UNASYN®-sulbactam, (an irreversible b c talactamase inhibitor)/Anpicillin was investigated in comparision to Cefapirin/Gentamycin at Department of Surgery, Chonnam National University Hospital from October, 1987 to Feburary, 1988. Randomly, twenty patient were treated with UNASYN® and other twenty patient were treated with Cefapirin/Gentamy ´n.
The summary of the result from the study was as follows.
In vitro sensitivity test of UNASYN® this drug showed highly sensitive for Staphylococcus aure s, 100%; Coagulase negative staphylococcus, 83.3%; Streptococcus not A group, 88.9%; E. coli, 70.3%, . d those were highly compared with that of Ampicilline alone and Cefapirin alone. But UNASYN® was sensitive only one of three for Pseudomonas species (39.3%) and moreover Gentamycin was more sensiti e than UNASYN® for Pseudomonas species.
Clinical satisfactory response was observed in 95% of both group, but numbers of CURE response we ie more in UNASYN® treated group than Cefapirin/Gentamycin treated group. And in the global assessme t of the clinical response, the efficacy was same in both group (90%), but numbers of EXELLENT responswere more in UNASYN® treated group (65%) than Cefapirin/Gentamycin treated group (40%).
Primary pathogens were eradicated in 76.9% of UNASYN® treated group, and 69.2% of Cefapirin/Ge - tamycin treated group.
During treatment, there was no adverse side effect in UNASYN® treated group.
As the whole, UNASYN® covered broad spectrum in antibiotic activity and was as effective aCefapirin/Gentamycin, and even more better than Cefapirin/Gentamycine in treatment of various surgical infections disease.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|